Senseonics (NYSE:SENS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $2.00 price objective on shares of Senseonics in a research note on Wednesday, August 14th.

Senseonics Stock Down 9.4 %

Shares of SENS opened at $0.32 on Thursday. The firm has a market capitalization of $172.72 million, a P/E ratio of -2.30 and a beta of 0.79. Senseonics has a 12-month low of $0.32 and a 12-month high of $0.75. The company has a current ratio of 3.11, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17. The firm has a fifty day moving average price of $0.41 and a 200-day moving average price of $0.46.

Senseonics (NYSE:SENS) last issued its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. Equities research analysts expect that Senseonics will post -0.13 earnings per share for the current year.

Institutional Trading of Senseonics

Hedge funds have recently added to or reduced their stakes in the business. RPO LLC purchased a new stake in shares of Senseonics during the fourth quarter valued at about $37,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Senseonics during the first quarter valued at about $91,000. Virtu Financial LLC purchased a new stake in shares of Senseonics during the first quarter valued at about $162,000. Cubist Systematic Strategies LLC lifted its position in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares during the last quarter. 12.36% of the stock is owned by hedge funds and other institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.